Portola Pharmaceuticals, Inc. kicked off the trading day on 08/13/19 with a price decrease of -0.98%, equivalent to -$0.3 relative change for the day. Taking a more long-term approach, PTLA had a 52-week range of $14.81 to $37.95. At the time of this article’s publishing, this stock is trading at $30.33 after starting the trading session at $29.40. Moving on, the stock has demonstrated a 52-week change amounting to 156.18, alongside an S&P500 52-Week Change of 117.13. At the time of writing, this stock’s 50-day Moving Average stands at $26.84, while the 200-day Moving Average of this stock is currently $27.22.
Currently, this company’s share volume is sitting at $2,186,479, but has maintained average daily volume of $1.04M. This stock has generated an average Year to Date volume of $1.23 million, alongside an average 20-day volume of $1.15 million. This publicly-traded company’s shares outstanding now amounts to $67.07 million, simultaneously with a float of $67.02 million. The organization now has a market capitalization sitting at $2.03 billion.
Portola Pharmaceuticals, Inc.(PTLA) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Portola Pharmaceuticals, Inc.’s current insider ownership accounts for 0.50%. According to the most recent latest insider trade that took place on Aug 08 this organization’s Director exercised an option 5,000 at the rate of 9.00, making the entire transaction hit 45,000 in total value, affecting insider ownership by 18,194. Preceding that transaction, on Aug 08 Company’s Director sold 5,000 at a price of 30.00, making the whole transaction’s value amount to 150,000. This particular insider is now the holder of 13,194 in total.
If we take a glance at the Ownership summary of Portola Pharmaceuticals, Inc.’s stock, 233 Institutional holders make up 95.77% of its total stock ownership. All together, they are the legal holders of 65,432,507 shares, which are valued at about $2,004,197,689 in total. If we focus on the top 3 stockholders for this publicly-traded organization, WELLINGTON MANAGEMENT GROUP LLP owns 9.07 million shares, with VANGUARD GROUP INC in 2nd place owning 5.83 million shares and BLACKROCK INC. in third place with total ownership of 5.14 million shares.
Portola Pharmaceuticals, Inc. (PTLA) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on Jun-19, the organization reported -$0.93 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$1.03) by $0.10.
The corporation racked up revenue of $22.17million for the previous financial quarter, compared to the mean analyst estimate of $19.18 million. This company achieved a net margin of -618.45 while generating a return on equity of -208.12. Portola Pharmaceuticals, Inc.’s full-quarter revenue increased by 608.73%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
Portola Pharmaceuticals, Inc.’s EPS decrease for this current 12-month fiscal period is -10.30%, and is forecasted to reach 21.50% in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Portola Pharmaceuticals, Inc., this organization’s Quick Ratio in the last reported quarter now stands at 4.80. The company has managed to achieve an average true range (ATR) of 1.30. Alongside those, its Beta score is 2.12.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 36.52 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 42.12, whereas its price to cash per share for the last quarter landed at 4.81.
In the same vein, PTLA’s Diluted EPS (Earnings per Share) trailing twelve month was posted at -5.19, a figure that is expected to reach -0.94 in the next reported quarter, and analysts expect it will be 21.50% at the market close of one year from today’s date.